Teva Pharmaceutical Industries Ltd.

Teva Pharmaceuticals and Blackstone Life Sciences (“BXLS”) today announced a $400m strategic funding agreement. Under the agreement, BXLS will provide Teva $400 million to fund ongoing and future development costs for duvakitug, spread over four years. As part of the funding arrangement and subject to the approval of duvakitug by the U.S. Food and Drug Administration (FDA), Teva will pay BXLS a milestone payment. BXLS will also be eligible to receive commercial milestones and low single-digit royalties on duvakitug worldwide sales, subject to customary terms and conditions.

Effective July 1st, 2014, Teva will be spearheaded by two commercial business units – Global Specialty Medicines (GSM), established in April 2013, and the newly-formed Global Generic Medicines group (GGM).

Teva sold Abic Biological Laboratories division, its veterinary unit, to Koffolk of the Phibro Group for $47m.

Teva Pharmaceutical has been given an option to invest a total of $23.5m in Andromeda Biotech, following phase III results of the DiaPep277 drug expected during 1H2008. Teva will receive exclusive rights to manufacture and sell the drug. If all options will be exercised, Teva will hold 30% of Andromeda.